Research programme: small molecule SHIP modulators - Neurogene Inc
Alternative Names: AQX-016A; AQX-100; AQX-100 series; AQX-1000 series; AQX-200 series; AQX-252; AQX-273; AQX-278; AQX-300 series; AQX-356; AQX-MN100; AQX-MN106; AQX-MN278; AQX-SHIP inhibitors; AXQ C5; SHIP1 inhibitorsLatest Information Update: 26 Dec 2023
At a glance
- Originator Aquinox Pharmaceuticals
- Class Small molecules
- Mechanism of Action Inositol-1,4,5-trisphosphate 5-phosphatase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological disorders; Haematological malignancies; Immunological disorders; Inflammation
- Discontinued Allergic conjunctivitis; Dry eyes
Most Recent Events
- 19 Dec 2023 Neurogene Inc has merged with Neoleukin Therapeutics to form Neurogene Inc
- 09 Aug 2019 Aquinox Pharmaceuticals merged with Neoleukin therapeutics to form Neoleukin Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-malignancies in Canada